OncoMed
OncoMed Pharmaceuticals was an American biotechnology company that developed antibody-based cancer therapies directed at cancer stem-cell signaling pathways.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
OncoMed Pharmaceuticals, Inc. was an American biotechnology company focused on discovering and developing targeted antibody therapies for cancer. The company was founded in August 2004 by University of Michigan investigators Michael Clarke and Max S. Wicha, whose academic work on cancer stem cells provided the scientific basis for OncoMed's technology platform. The company licensed relevant cancer stem-cell technologies from the University of Michigan and sought to translate them into biologic medicines intended to interfere with tumor initiation, maintenance, recurrence, and resistance to conventional treatment. OncoMed's research concentrated particularly on signaling pathways associated with cancer stem-cell biology. Its development portfolio included antibodies directed at the Notch and Wnt pathways, among other targets. Candidates included demcizumab, an anti-DLL4 antibody; vantictumab, an anti-Frizzled antibody; ipafricept; tarextumab; brontictuzumab; OMP-305B83; and OMP-131R10. The company sponsored the nonproprietary names vantictumab and demcizumab in 2012. None of the company's therapies reached the commercial market during OncoMed's independent existence. The business consolidated operations previously located in Mountain View and Palo Alto at a single campus in Redwood City's Seaport Centre in 2007. Its headquarters were located in a building that had previously been associated with NeXT. By 2013, OncoMed had 83 employees and had developed into a publicly traded clinical-stage biotechnology company. It completed its initial public offering in 2013 and traded on the Nasdaq under the symbol OMED. OncoMed pursued development through collaborations with larger pharmaceutical companies. In 2014, it entered into an agreement with Celgene covering demcizumab and five additional biologic candidates. Other programs were partnered with Bayer and GlaxoSmithKline. In the middle of the 2010s, clinical observations of mild-to-moderate bone-related adverse effects in trials of ipafricept and vantictumab led to pauses in enrollment and dosing. The setbacks contributed to a substantial decline in the company's share price and complicated the prospects for its pipeline. The company operated in an increasingly competitive cancer-stem-cell therapeutics field. Stemline Therapeutics and Verastem were identified as direct public-company competitors, while larger pharmaceutical organizations including Boston Biomedical, GlaxoSmithKline, Astellas, Sanofi, and Pfizer also investigated related approaches. As of January 2017, OncoMed had seven clinical-stage programs and four discovery-stage investigations, but no approved or marketed therapy. In April 2019, Mereo BioPharma acquired OncoMed, after which OncoMed was delisted from Nasdaq and ceased to operate as an independent public company.
History
OncoMed Pharmaceuticals was established in August 2004 by Michael Clarke and Max S. Wicha, two University of Michigan investigators associated with the emerging scientific field of cancer stem-cell research. Their work proposed that a distinct subset of tumor cells could help initiate and sustain cancers, contribute to relapse, and influence resistance to treatment. OncoMed was created to commercialize related discoveries through antibody-based medicines aimed at biological pathways used by these cells. The company licensed its underlying cancer stem-cell technologies from the University of Michigan. During its early years, OncoMed operated from locations in Mountain View and Palo Alto, California. In 2007, it consolidated those activities at the Seaport Centre in Redwood City, creating a single headquarters campus. One of the buildings had previously been associated with NeXT. The move reflected the company's transition from an academic-originated startup into a more established biotechnology development organization. The company developed a portfolio of experimental monoclonal antibodies directed at signaling systems implicated in tumor growth and cancer stem-cell maintenance. In 2012, it sponsored the USAN names demcizumab for an anti-DLL4 antibody and vantictumab for an anti-Frizzled antibody. These programs represented two central elements of its strategy: interfering with Notch-related DLL4 signaling and with Wnt-related Frizzled signaling. Other candidates in the pipeline included ipafricept, tarextumab, brontictuzumab, OMP-305B83, and OMP-131R10. OncoMed became a public company in 2013, listing on Nasdaq under the symbol OMED. At that time it had 83 employees. Paul Hastings had served as chief executive officer since 2006. Wicha continued as a consultant while directing the University of Michigan Comprehensive Cancer Center, and Clarke later held a position at Stanford University. The company also maintained relationships with major pharmaceutical partners to fund and advance its clinical programs. In 2014, OncoMed entered a development agreement with Celgene covering demcizumab and five other biologics. Its other programs were associated with collaborations involving Bayer and GlaxoSmithKline. These alliances gave OncoMed access to larger development and commercialization resources while retaining its identity as a specialized oncology biotechnology company. Clinical development produced important setbacks. In the middle of 2014, trials of ipafricept and vantictumab showed mild-to-moderate bone-related adverse effects in some Phase I participants. OncoMed halted enrollment and dosing in the affected studies. The events damaged market confidence and were associated with a sharp fall in the company's share price. Although the company continued to describe a broad development pipeline, the safety findings illustrated the difficulty of translating pathway-directed cancer-stem-cell biology into tolerable human therapies. By January 2017, OncoMed had seven clinical-stage drug candidates and four discovery-stage investigations. None had become an approved marketed medicine. Its competitive environment included Stemline Therapeutics and Verastem, which were identified as public companies focused on cancer-stem-cell therapeutics, as well as larger organizations investigating related approaches, including Boston Biomedical, GlaxoSmithKline, Astellas, Sanofi, and Pfizer. In April 2019, Mereo BioPharma acquired OncoMed. The transaction resulted in OncoMed's delisting from Nasdaq and brought the company to an end as an independent public biotechnology business. Its historical significance lies primarily in its role as an early commercial developer of cancer-stem-cell-targeted antibodies and in the partnerships and clinical experience generated by that approach.
- 2019
Acquisition and delisting
[1]Mereo BioPharma acquires OncoMed in April, and OncoMed is delisted from Nasdaq.
- 2014
Celgene development collaboration
[1]OncoMed and Celgene agree to collaborate on demcizumab and five additional biologic candidates.
- 2013
Nasdaq listing
[1]OncoMed becomes publicly traded on Nasdaq under the symbol OMED.
- 2012
Names sponsored for demcizumab and vantictumab
[1]OncoMed sponsors the USAN names for its anti-DLL4 and anti-Frizzled antibody programs.
- 2007
Operations consolidate in Redwood City
[1]The company combines its Mountain View and Palo Alto operations at the Seaport Centre campus in Redwood City, California.
- 2004
OncoMed is founded
[1]Michael Clarke and Max S. Wicha establish OncoMed to develop therapies based on cancer stem-cell research and licensed University of Michigan technology.
Products and positioning
A clinical-stage oncology biotechnology company focused on antibody therapeutics designed to target cancer stem cells and related developmental signaling pathways.
Monoclonal antibody · 2012
Demcizumab
An experimental human IgG2 antibody directed against DLL4, a ligand in the Notch signaling pathway. OncoMed sponsored the drug's USAN name in 2012 and later developed the program with Celgene as a potential cancer-stem-cell and oncology therapy. It remained investigational and was not marketed.
Monoclonal antibody · 2012
Vantictumab
An experimental human IgG2 anti-Frizzled antibody designed to interfere with Wnt-related signaling. The program was one of OncoMed's principal cancer-stem-cell projects and was developed in collaboration with Bayer. Clinical development encountered bone-related safety findings that resulted in a pause of enrollment and dosing.
Biologic oncology candidate
Ipafricept
An investigational biologic associated with OncoMed's Wnt-pathway development strategy and partnered with Bayer. Phase I studies reported mild-to-moderate bone-related adverse effects among participants, contributing to a halt in enrollment and dosing. It did not reach commercialization during OncoMed's independent operation.
Monoclonal antibody
Tarextumab
An experimental oncology antibody in OncoMed's cancer-stem-cell-focused pipeline. The program was developed in collaboration with GlaxoSmithKline and remained a clinical-stage investigational medicine rather than a marketed product.
Monoclonal antibody
Brontictuzumab
An investigational biologic included in OncoMed's oncology pipeline and developed in collaboration with GlaxoSmithKline. It was intended to address signaling associated with tumor biology and cancer stem cells but did not become a commercial medicine during OncoMed's independent existence.
Biologic oncology candidate
OMP-305B83
A clinical-stage biologic candidate from OncoMed's oncology pipeline. The program was among the candidates included in the company's collaboration with Celgene and remained under development rather than being launched as a marketed therapy.
Biologic oncology candidate
OMP-131R10
An investigational biologic candidate developed by OncoMed and included in its Celgene collaboration. It remained part of the research and development portfolio and was not commercially launched by OncoMed.
Brand decisions
2019
Accept acquisition by Mereo BioPharmaM&ABackground
OncoMed remained a clinical-stage biotechnology company without a marketed therapy.
Action taken
Mereo BioPharma acquired OncoMed in April 2019.
Aftermath
OncoMed was delisted from Nasdaq and no longer operated as an independent public company.
2014
Pause selected ipafricept and vantictumab clinical activityStrategyBackground
Phase I participants in studies of programs partnered with Bayer showed mild-to-moderate bone-related side effects.
Action taken
OncoMed halted enrollment and dosing in the affected trials while the safety observations were assessed.
Aftermath
The development setbacks contributed to a sharp decline in OncoMed's share price and increased uncertainty around its pipeline.
2014
Enter a multi-program development agreement with CelgeneM&ABackground
OncoMed sought large-pharmaceutical support to advance its cancer-stem-cell biologics.
Action taken
The company entered an agreement with Celgene covering demcizumab and five additional biologic candidates.
Aftermath
The agreement expanded external collaboration around OncoMed's clinical pipeline, although the referenced material does not establish a commercial product outcome.
Recent events
- 2019
Mereo BioPharma acquires OncoMed[1]
M&A · Leadership change
Mereo BioPharma acquired OncoMed in April 2019, ending OncoMed's existence as an independent Nasdaq-listed company.
- 2014
Bone-related adverse effects affect ipafricept and vantictumab studies[1]
Other · Product generation
Mild-to-moderate bone-related side effects observed among some Phase I participants led to pauses in enrollment and dosing for partnered programs involving ipafricept and vantictumab.
- 2014
OncoMed enters cancer stem-cell therapeutics agreement with Celgene[1]
M&A · Other
OncoMed and Celgene agreed to develop demcizumab and five additional OncoMed biologic candidates.
- 2013
OncoMed completes Nasdaq initial public offering[1]
Other
OncoMed became a publicly traded biotechnology company on Nasdaq under the ticker OMED.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/oncomed · Editorial policy · How profiles are compiled